Anella Saviano, Adel Abo Manosour, Federica Raucci, Francesco Merlino, Noemi Marigliano, Anna Schettino, Mussarat Wahid, Jenefa Begum, Andrew Filer, Julia E Manning, Gian Marco Casillo, Marialuisa Piccolo, Maria Grazia Ferraro, Simona Marzano, Pasquale Russomanno, Rosa Bellavita, Carlo Irace, Jussara Amato, Mohammed Alfaifi, Peter Rimmer, Tariq Iqbal, Stefano Pieretti, Valentina Vellecco, Francesco Caso, Luisa Costa, Roberto Giacomelli, Raffaele Scarpa, Giuseppe Cirino, Mariarosaria Bucci, Helen M McGettrick, Paolo Grieco, Asif Jilani Iqbal, Francesco Maione
OBJECTIVES: Interleukin (IL) 17s cytokines are key drivers of inflammation that are functionally dysregulated in several human immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD). Targeting these cytokines has some therapeutic benefits, but issues associated with low therapeutic efficacy and immunogenicity for subgroups of patients or IMIDs reduce their clinical use. Therefore, there is an urgent need to improve the coverage and efficacy of antibodies targeting IL-17A and/or IL-17F and IL-17A/F heterodimer...
August 14, 2023: Annals of the Rheumatic Diseases